11:26:11 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMERK Equities
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo.


2022-02-15 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2021-01-04 Extra Bolagsstämma 2021
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-30 Kvartalsrapport 2020-Q1
2020-03-31 Bokslutskommuniké 2019
2019-12-31 Kvartalsrapport 2019-Q3
2019-12-20 Extra Bolagsstämma 2019
2019-09-30 Kvartalsrapport 2019-Q2
2019-06-30 Kvartalsrapport 2019-Q1
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2019-03-31 Bokslutskommuniké 2018
2018-12-31 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-07-02 Split SOFTX 1:50
2018-06-07 Kvartalsrapport 2018-Q1
2021-02-03 08:30:00
SoftOx Solutions AS and the Norwegian Defence Research Establishment (FFI) have
signed a letter of intent with a plan to adapt the civilian products the company
develops to be used for military purposes. SoftOx Solutions AS currently
provides hand and surface disinfection products without alcohol that possess
different and unique properties than current products on the market. The company
is also working on the development of a wound wash product, a product that
prevents and removes wound infections and a product for the treatment of viral
infections in the respiratory tract.

The parties are now working towards the goal of signing a 3-5-year collaboration
agreement by 1 April 2021. If the research and development collaboration (R&D)
is signed in April, the parties will together carry out basic research, testing
and experimentation of SoftOx products to identify the effects of different
products for the operational capability of the Armed Forces. "We want the
collaboration to contribute to improving the availability of operational
personnel in exercises and operations and ensure the best possible prevention
and treatment of wounds and infectious injuries that occur in the Armed Forces'
operations," according to CEO Geir Almås of SoftOx Solutions.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Mail: geir.almaas@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (Softx, listed on the Euronext Growth, Oslo)
is a Norwegian BioTech company based in Oslo with the aim of helping to combat
major threats to human health, namely the emergence of antimicrobial resistance
(AMR), biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com